Revelation Biosciences, Inc.
Built from real-time financials, refreshed daily. For a full Analyst Grade with bull/bear case, price targets, and qualitative risk analysis, generate a REVB research report →
About the company
Revelation Biosciences, Inc. is a biopharmaceutical firm currently in its clinical development phase, dedicated to the advancement and commercialization of treatments and diagnostic tools targeting the immune system. The company's therapeutic pipeline includes promising candidates such as GEM-AKI, which is being developed as a potential therapy for both the prevention and management of acute kidney injury, and GEM-CKD, intended for the prevention and treatment of chronic kidney disease.
- CEO
- James Rolke
- IPO
- 2020
- Employees
- 8
- HQ
- San Diego, CA, US
Price Chart
- Market Cap
- $4.22M
- P/E
- -0.08
- P/S
- 0.00
- P/B
- 0.27
- EV/EBITDA
- 0.91
- Div Yield
- 0.00%
- Gross Margin
- 0.00%
- Op Margin
- 0.00%
- Net Margin
- 0.00%
- ROE
- -107.66%
- ROIC
- -73.23%
- Revenue
- $0 · 0.00%
- Net Income
- $-8,913,649 · 40.73%
- EPS
- $-23.95 · 72.68%
- Op Income
- $-9,070,814
- FCF YoY
- 54.91%
- 52W High
- $12.88
- 52W Low
- $0.88
- 50D MA
- $1.05
- 200D MA
- $2.66
- Beta
- -0.12
- Avg Volume
- 61.87K
Get TickerSpark's AI analysis on REVB
Create an account to generate AI analysis on any ticker — technical setup, analyst consensus, earnings watch, insider pulse, financial health, and peer context. Ready in about a minute.
Get Pro Access →Already have an account? Log in
Recent insider transactions
Who's buying, who's selling, and how much.
| Date | Insider | Type | Shares |
|---|---|---|---|
| Apr 30, 26 | Rolke James | other | 10,115 |
| Apr 30, 26 | Zygmont Chester Stanley III | other | 13,285 |
| Feb 3, 26 | ROPER JESS | other | 1,591 |
| Feb 3, 26 | Chawla Lakhmir S | other | 2,261 |
| Feb 3, 26 | CARVER JENNIFER | other | 1,661 |
| Feb 3, 26 | Rolke James | other | 8,521 |
| Feb 4, 26 | Zygmont Chester Stanley III | other | 13,100 |
| Jan 8, 26 | Rolke James | other | 532,829 |
| Jan 8, 26 | Zygmont Chester Stanley III | other | 78,145 |
| Jan 8, 26 | CARVER JENNIFER | other | 41,981 |
Our REVB coverage
Recent articles, reports, and earnings notes.
No research on REVB yet
For a full analyst-grade research report — grades, price targets, financials, chart analysis — generate one on demand.
Generate REVB report →Similar companies
Peers in the same neighborhood.